Advanced BioScience Laboratories, Inc. Awarded National Institutes of Health (NIH) Contract to Fund Up to $102 Million in Biologics Manufacturing and Characterization Services

ROCKVILLE, Md.--(BUSINESS WIRE)--Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff. The contract has a funding potential of up to $102 million over 10 years, subject to availability of annual appropriations.